Susan Jones‐Bolin

1.4k total citations
14 papers, 769 citations indexed

About

Susan Jones‐Bolin is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Susan Jones‐Bolin has authored 14 papers receiving a total of 769 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Oncology and 3 papers in Hematology. Recurrent topics in Susan Jones‐Bolin's work include Angiogenesis and VEGF in Cancer (4 papers), Cancer Research and Treatments (3 papers) and Cancer Treatment and Pharmacology (3 papers). Susan Jones‐Bolin is often cited by papers focused on Angiogenesis and VEGF in Cancer (4 papers), Cancer Research and Treatments (3 papers) and Cancer Treatment and Pharmacology (3 papers). Susan Jones‐Bolin collaborates with scholars based in United States, Netherlands and France. Susan Jones‐Bolin's co-authors include Bruce Ruggeri, Craig A. Dionne, Kam-Fai Tse, Mark J. Levis, B. Douglas Smith, Donald Small, Rui Zheng, Brenda R. Baldwin, Kathryn Hunter and Hugh Zhao and has published in prestigious journals such as Blood, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Susan Jones‐Bolin

13 papers receiving 745 citations

Peers

Susan Jones‐Bolin
Shengyan Xiang United States
A M Martelli Italy
Brock Whittenberger United States
Sarah M. Jacobs-Helber United States
Ningfei An United States
Daniela Di Marcantonio United States
Annette Eckardt United States
Anu Gupta United States
D Oberberg Germany
Rosie Xing Canada
Shengyan Xiang United States
Susan Jones‐Bolin
Citations per year, relative to Susan Jones‐Bolin Susan Jones‐Bolin (= 1×) peers Shengyan Xiang

Countries citing papers authored by Susan Jones‐Bolin

Since Specialization
Citations

This map shows the geographic impact of Susan Jones‐Bolin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Jones‐Bolin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Jones‐Bolin more than expected).

Fields of papers citing papers by Susan Jones‐Bolin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Jones‐Bolin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Jones‐Bolin. The network helps show where Susan Jones‐Bolin may publish in the future.

Co-authorship network of co-authors of Susan Jones‐Bolin

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Jones‐Bolin. A scholar is included among the top collaborators of Susan Jones‐Bolin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Jones‐Bolin. Susan Jones‐Bolin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Sanchez, Eric, Mingjie Li, Jennifer Li, et al.. (2012). CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma. Leukemia Research. 36(11). 1422–1427. 19 indexed citations
2.
Berkers, Celia R., Yves Leestemaker, Karianne Schuurman, et al.. (2012). Probing the Specificity and Activity Profiles of the Proteasome Inhibitors Bortezomib and Delanzomib. Molecular Pharmaceutics. 9(5). 1126–1135. 37 indexed citations
3.
4.
Ruggeri, Bruce, Ted L. Underiner, Diane E. Gingrich, et al.. (2007). CEP-11981: A potent TIE-2/Pan-VEGF-R inhibitor with broad kinase inhibitory activity exhibits significant antitumor and antiangiogenic efficacy in preclinical tumor models. Molecular Cancer Therapeutics. 6. 2 indexed citations
5.
Jones‐Bolin, Susan & Bruce Ruggeri. (2007). Orthotopic Model of Human Pancreatic Ductal Adenocarcinoma and Cancer Cachexia in Nude Mice. Current Protocols in Pharmacology. 37(1). Unit 14.3–Unit 14.3. 10 indexed citations
6.
Jones‐Bolin, Susan & Bruce Ruggeri. (2007). Metastatic Model of Colon Carcinoma in Mice: Utility in the Study of Tumor Growth and Progression. Current Protocols in Pharmacology. 38(1). Unit 14.5–Unit 14.5. 1 indexed citations
7.
Jones‐Bolin, Susan & Bruce Ruggeri. (2007). Orthotopic Models of Human Gastric Carcinoma in Nude Mice: Applications for Study of Tumor Growth and Progression. Current Protocols in Pharmacology. 37(1). Unit 14.4–Unit 14.4. 7 indexed citations
8.
Jones‐Bolin, Susan, Hugh Zhao, Kathryn Hunter, Andres J. Klein–Szanto, & Bruce Ruggeri. (2006). The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Molecular Cancer Therapeutics. 5(7). 1744–1753. 38 indexed citations
9.
Jones‐Bolin, Susan, Kathryn Hunter, Hugh Zhao, Andres J. Klein–Szanto, & Bruce Ruggeri. (2005). Trk inhibitors provide better efficacy than a VEGF-R kinase inhibitor in combination with gemcitabine on improving survival in an orthotopic model of human PDAC. Cancer Research. 65. 711–712. 1 indexed citations
10.
Dobrzański, Paweł, Kathryn Hunter, Susan Jones‐Bolin, et al.. (2004). Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist. Cancer Research. 64(3). 910–919. 139 indexed citations
11.
Strock, Christopher J., Jong‐In Park, Mark Rosen, et al.. (2003). CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.. PubMed. 63(17). 5559–63. 83 indexed citations
12.
Clermont, AC, et al.. (2002). Retinal Vascular Leakage in Early Diabetes is Normalized In Vivo by the Oral VEGF Receptor Kinase Inhibitor, CEP-7055. Investigative Ophthalmology & Visual Science. 43(13). 3862–3862. 1 indexed citations
13.
Levis, Mark J., Kam-Fai Tse, Rui Zheng, et al.. (2002). A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 99(11). 3885–3891. 378 indexed citations
14.
Jones‐Bolin, Susan. (1998). Effect of promoter and intron 2 polymorphisms on murine lung K-ras gene expression. Carcinogenesis. 19(8). 1503–1508. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shengyan Xiang Breakdown of academic impact, for papers by A M Martelli Breakdown of academic impact, for papers by Brock Whittenberger Breakdown of academic impact, for papers by Sarah M. Jacobs-Helber Breakdown of academic impact, for papers by Ningfei An Breakdown of academic impact, for papers by Daniela Di Marcantonio Breakdown of academic impact, for papers by Annette Eckardt Breakdown of academic impact, for papers by Anu Gupta Breakdown of academic impact, for papers by D Oberberg Breakdown of academic impact, for papers by Rosie Xing
Rankless by CCL
2026